Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Haemonetics (HAE) over the last 16 years, with Q4 2025 value amounting to $539.9 million.

  • Haemonetics' Total Current Liabilities rose 11319.02% to $539.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $539.9 million, marking a year-over-year increase of 11319.02%. This contributed to the annual value of $578.1 million for FY2025, which is 9245.86% up from last year.
  • Haemonetics' Total Current Liabilities amounted to $539.9 million in Q4 2025, which was up 11319.02% from $548.3 million recorded in Q3 2025.
  • Haemonetics' 5-year Total Current Liabilities high stood at $578.1 million for Q1 2025, and its period low was $180.5 million during Q3 2022.
  • Its 5-year average for Total Current Liabilities is $326.9 million, with a median of $263.2 million in 2022.
  • In the last 5 years, Haemonetics' Total Current Liabilities crashed by 4401.08% in 2021 and then surged by 11319.02% in 2025.
  • Haemonetics' Total Current Liabilities (Quarter) stood at $288.5 million in 2021, then dropped by 21.35% to $226.9 million in 2022, then rose by 15.37% to $261.8 million in 2023, then fell by 3.26% to $253.2 million in 2024, then skyrocketed by 113.19% to $539.9 million in 2025.
  • Its last three reported values are $539.9 million in Q4 2025, $548.3 million for Q3 2025, and $531.4 million during Q2 2025.